Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 1,936

Document Document Title
JP2597649B2
The present invention provides a tracheobronchodilator comprising 15-keto-PGEs, reduced in stimuli against bronchi and other side effects.  
JP2596575B2
Process for the production of alpha -hydroxy-bicyclo[3.3.0]octane derivatives of formula (I), where A is the double-bound residue -O-X-O-, X having the notation of a straight or branched-chain alkalin with 1-7 C atoms or the residue =CH-...  
JP2593540B2
PCT No. PCT/DE88/00149 Sec. 371 Date Nov. 13, 1989 Sec. 102(e) Date Nov. 13, 1989 PCT Filed Mar. 11, 1988 PCT Pub. No. WO88/07050 PCT Pub. Date Sep. 22, 1988.The invention relates to a process for the production of (+)-bicyclo[3.3.0]octa...  
JPH09502964A
The present invention relates to cyclopentane heptanoic or cyclopentane heptenoic acid, 2-hydrocarbyl sulfonamidomethyl, and derivatives thereof, useful as therapeutic agents. In particular, the therapeutic agents of this invention are u...  
JP2592204B2
PURPOSE: To provide an intraocular tension depressant little in side effect, excellent in therapeutic effect, useful for curing the intraocular tension rise concomitant with glaucoma or hypertension, containing, as active ingredient, a d...  
JPH09501943A
PCT No. PCT/EP94/02855 Sec. 371 Date May 29, 1996 Sec. 102(e) Date May 29, 1996 PCT Filed Aug. 29, 1994 PCT Pub. No. WO95/06634 PCT Pub. Date Mar. 9, 1995The invention relates to 9-chloro-prostaglandin derivatives of formula I (I) in whi...  
JP2579193B2  
JPH0920788A
To obtain a new vinyltin compound capable of producing rostaglandins useful as e.g. a swine-oxytocic with a few processes and an inexpensive reaction reagent, by reaction of a protecting group-bearing specific epoxysilicon compound with ...  
JP2571250B2  
JPH08310956A
PURPOSE: To obtain the subject inhibitor containing a specific active ingredient, strongly suppressing chemotaxis caused by a chemokine such as monocyte migration factor MCP-1/MCAF, etc., and/or migration of smooth muscle cell of blood v...  
JP2543396B2  
JPH08246977A
PURPOSE: To perform further precise control of an injection amount of fuel and an injection timing. CONSTITUTION: A rotation angle sensor 120 is provided with a sensor body 123, containing a magnet 121 and a coil 122, and a magnetic flux...  
JP2536026B2  
JP2536516B2
NEW MATERIAL:A compound shown by formula I {R<1> is 1-10C aliphatic group (which may contain 0-3 unsaturated bonds and may be replaced with lower alkoxy or lower alkoxycarbonyl) or H; X is H or OH-protecting group; Y is group shown by fo...  
JP2529095B2
PURPOSE: To obtain the subject new prostaglandin E2 having strong uterus contraction action and suppressing the embedding of egg and useful as an uterus contracting agent or a medicine for artificial abortion, etc. CONSTITUTION: 13, 14-D...  
JPH08208598A
PURPOSE: To obtain the subject composition markedly improved in the stability of prostaglandin compounds, high in safety, thus useful as a medicine, etc., comprising a prostaglandin compound and a carboxylic acid diglyceryl ester. CONSTI...  
JPH08208599A
PURPOSE: To obtain the subject physically stable compound expressed by a specific formula, easy to purify and handle, and having pharmacological action on various kinds of nephrotic diseases and ischemic cardiopathy, etc. CONSTITUTION: T...  
JP2515458B2
PURPOSE: To obtain a wound curing promoter, especially a curing promoter for corneal damage containing a 15-keto-prostaglandin compound as an active ingredient. CONSTITUTION: A wound curing promoter containing a 15-keto-prostaglandin com...  
JPH08169832A
PURPOSE: To obtain a skin application composition containing a 7- thiaprostaglandin compound, useful as an agent for the treatment of cutaneous ulcer having the lesion part near the surface of the skin, having stability and enabling quic...  
JP2511579B2
A compound of the formula: wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L and M is not hydrogen atom and that the five-membered ring may have one or two double bonds, ...  
JP2503073B2  
JPH08143542A
PURPOSE: To obtain a new unsaturated aldehyde derivative, useful as an intermediate for medicines, agrochemicals, perfumes, analytical reagents, etc., and capable of industrially, advantageously and readily producing prostaglandin deriva...  
JPH0892096A
PURPOSE: To obtain an inhibitor for propagation or migration of vascular smooth muscle cell containing specific isocarbacylines and expectable of availability to prevent or cure, etc., of restenosis after percutaneous coronary arteriopla...  
JPH08502495A
Compounds of the formula where the dotted line represents a bond or the absence of a bond, the wavy lines represent bonds which are either in cis or trans configuration; R1 represents H, or CO-R2 where R2 is lower alkyl of 1 to 6 carbons...  
JPH0819040B2
The phenylalkan(en)oic acids of the formula: wherein the substituants are defined as in the disclosure, possess an antagonism on leukotriene B4, and therefore, are useful for the prevention and treatment of several diseases induced by le...  
JPH08501546A
This invention relates to a prostaglandin-bisphosphonate compound of the formula: and its pharmaceutically acceptable salts. The claimed compounds are effective as delivery agents of prostaglandins to treat osteoporosis and related bone ...  
JPH089543B2  
JPH085836B2  
JPH08500597A
The invention concerns 9-chloroprostaglandin esters and amides of general formula (I), methods of preparing them and their use as drugs.  
JPH07116134B2
NEW MATERIAL:The compound of formula I [the double line is cis or trans double bond; G<1> is -CO2R<5> (R<5> are H, 1-10C alkyl, etc.), etc.; R<1> is H, methyl, etc.; R<2> is unsubstituted 5-8C alkyl, (substituted) alicyclic group, etc.; ...  
JPH07116135B2  
JPH07116136B2  
JPH07113012B2  
JPH07309833A
PURPOSE: To obtain the new subject compound having strong and long lasting intraocular tension-reducing activity, free from side effect and useful as an agent for prophylaxis and/or treatment of glaucoma. CONSTITUTION: This compound is a...  
JPH07107020B2
Cyclodextrin clathrates of carbacyclin analogs of general Formula I (I) wherein R1 is hydrogen, alkyl or alkenyl of up to 10 carbon atoms, A is a -CH2CH2-, trans-CH=CH-, or -C 3BOND C- group, W is a free or functionally modified hydroxym...  
JPH07103096B2  
JPH07285930A
PURPOSE: To provide a new PGE1 analogue having a more selective and stronger antiulcer activity than those of the known PGE1 analogues and excellent in persistence. CONSTITUTION: A compound of formula I (A is O, NH; B is -NHCO-, -CONH-, ...  
JPH0796497B2  
JPH0794451B2  
JPH0791218B2
The present invention relates to a new prostagrandine I analogous compounds represented by the following formula (I) and (II). wherein R1 is a hydrogen atom or alkyl group, at least one of R2 and/or R2' are a halogen atom, an alkyl group...  
JPH07238068A
PURPOSE: To obtain a new prostaglandin E1 analog, having suppressing actions on blood platelet agglutination and vasodepressor activities and useful for treating, etc., peripheral circulatory disorder. CONSTITUTION: This compound is expr...  
JPH07233145A
PURPOSE: To obtain a new prostaglandin E1 amide homologue which is useful for treating digestive ulcer because it has high durative actions to protect cells and inhibit the secretion of gastric juice. CONSTITUTION: A compound of formula ...  
JPH0772170B2
This invention relates to a process for making a compound of formula Iin the form of a stereoisomer or mixture thereof, wherein R is hydrogen, lower alkyl; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy l...  
JPH0768158B2
PCT No. PCT/DE86/00483 Sec. 371 Date Aug. 7, 1987 Sec. 102(e) Date Aug. 7, 1987 PCT Filed Nov. 28, 1986 PCT Pub. No. WO87/03582 PCT Pub. Date Jun. 18, 1987.The invention relates to a process for the production of (5-chloro-3-hydroxycyclo...  
JPH07188025A
PURPOSE: To obtain a medicine inhibiting cell migration caused by a chemokine, e.g. monocyte migration factor MCP-1/MCAF, comprising a specific prostaglan din E and/or its enantiomer as an effective component. CONSTITUTION: An inhibitor ...  
JPH0764808B2
The invention relates to 9-halo-15-cycloalkyl prostaglandin derivatives of Formula I (I) wherein R1 is hydrogen or methyl, R2 is fluorine or chlorine, n is 0 or 1, and, if R1 is hydrogen, the salts thereof with physiologically compatible...  
JPH0764733B2  
JPH0761995B2  
JPH0759505B2  
JPH07505129A
PCT No. PCT/EP92/02653 Sec. 371 Date May 27, 1994 Sec. 102(e) Date May 27, 1994 PCT Filed Nov. 19, 1992 PCT Pub. No. WO93/11105 PCT Pub. Date Jun. 10, 1993.Leukotriene-B4 derivatives of formula I (I) their salts with physiologically comp...  

Matches 601 - 650 out of 1,936